Oxagen Limited
Oxagen is focused on becoming a significant biopharmaceutical company, developing a pipeline of novel drugs to treat inflammatory diseases. The Company has created a portfolio of valuable drug targets centered on the highly attractive class of receptors, GPCRs. Through its heritage in human genetics, Oxagen has validated a number of GPCR targets, many of them novel, and selected the most promising as drug targets.
Oxagen was established in April 1997 and initially focused on identifying drug targets through genetics. Since 2003 the Company has focused on building a drug discovery and development capability and pipeline around GPCR targets. Oxagen’s lead compound OC000459 is a novel oral anti-inflammatory agent for the treatment of allergic disease and has successfully completed Phase IIa trials demonstrating efficacy in both asthma and allergic rhinitis. Phase IIb dose-range finding studies are currently underway. The Company is based in Milton Park, south of Oxford.
Contact Details
Executives
Chairman
David C. U'Prichard
CEO and Chief Scientific Officer
Mark Payton